Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
| Beth Israel Deaconess Medical Center | OTHER |
| Cedars-Sinai Medical Center | OTHER |
Not provided
Not provided
Not provided
A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery
This trial is a single-center, randomized, double-blind placebo-controlled Trial of Nam versus placebo in patients undergoing on-pump cardiac surgery. After screening and enrollment, patients will be stratified according to CKD status (eGFR<45 ml/min/m2) and surgical site and randomized in a 1:1 manner to receive either Nam 3 grams or placebo on the day of surgery and post-surgical days one and two.
The overall trial duration is planned for 42 months, consisting of 39 months of active recruitment and treatment period and three months of follow-up from the last patient enrolled.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oral niacinamide | Experimental |
| |
| Matched placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Niacinamide | Drug | Niacinamide 3 grams on the day of surgery and post-surgical days one and two |
|
| Measure | Description | Time Frame |
|---|---|---|
| Troponin T AUC | Troponin T AUC, composed of single daily serum measurements | From baseline to three days after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Mean difference in uQuin/Tryp ratio AUC | Mean difference in uQuin/Tryp ratio AUC composed of single daily serum measurements | From baseline to three days after surgery |
| Mean difference in eGFR |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants with the following Adverse Events and Serious Adverse Events |
|
Inclusion Criteria
Procedures include:
Risk factors for surgery related to adverse cardiovascular outcomes include one or more of the following:
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ali Poyan Mehr, MD | Contact | 4152644750 | ali.x.poyanmehr@kp.org |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kaiser Permanente San Francisco Medical Center | Recruiting | San Francisco | California | 94115 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38689404 | Derived | Scurt FG, Bose K, Mertens PR, Chatzikyrkou C, Herzog C. Cardiac Surgery-Associated Acute Kidney Injury. Kidney360. 2024 Jun 1;5(6):909-926. doi: 10.34067/KID.0000000000000466. Epub 2024 May 1. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015427 | Reperfusion Injury |
| D058186 | Acute Kidney Injury |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D009536 | Niacinamide |
| ID | Term |
|---|---|
| D009539 | Nicotinic Acids |
| D000147 | Acids, Heterocyclic |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Matched placebo on the day of surgery and post-surgical days one and two |
|
Mean difference in eGFR (CKD-EPI formula)
| From baseline through day 5. |
| From baseline through day 90 |
| Length of index hospital stay. | • Mean length of index hospital stay (days) | From baseline through day 90 |
| Length of intensive care unit stay. | • Mean length of intensive care unit stay (days) | From baseline through day 90 |
| Perioperative inotropic-score and vasoactive-inotropic score. | • Mean inotropic-score and vasoactive-inotropic score | At 6, 12, 24, and 48 hours post operatively |
| Perioperative fluid volume administration. | • Mean daily perioperative fluid volume administration | From baseline through day 2 |
| Perioperative brain-natriuretic peptide AUC | BNP AUC, composed of single daily serum measurements | From baseline to three days after surgery |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D006573 |
| Heterocyclic Compounds, 1-Ring |